The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.
 
Benjamin Philip Levy
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Novocure; Pfizer; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Turning Point Therapeutics (Inst)
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Wu-Chou Su
Consulting or Advisory Role - Bayer Schering Pharma; Lilly; Merck; MSD Oncology
 
Scott M. Herbert
Employment - Nexus Health Systems
 
Tsung-Ying Yang
Consulting or Advisory Role - AstraZeneca; Takeda
Travel, Accommodations, Expenses - MERCK
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sun Pharma Advanced Research Company (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Venus Oncology (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Diego Luigi Cortinovis
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech; Seagen; takeda
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Manuel Domine
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme; Pfizer; Takeda
 
Konstantinos Leventakos
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Atsushi Horiike
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EP-SOGO; Kyowa Kirin; Lilly Japan; Merck; Novartis; Taiho Oncology
Research Funding - BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Nihonkayaku (Inst)
 
Edward Pan
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Daisy Lin
Employment - Daiichi Sankyo
 
Xiaoyu Jia
Employment - Daiichi Sankyo/Astra Zeneca; Regeneron
Stock and Other Ownership Interests - Regeneron
 
Priyanka Basak
No Relationships to Disclose
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichi-iko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQVIA (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Networks (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - CancerNet Japan; JAMT